Evaluation of How Long Immune Responses to SARS-CoV-2 Persist Following COVID-19 Vaccinatio
Phase 1
- Conditions
- COVID-19Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2021-000349-42-SE
- Lead Sponsor
- Sahlgrenska Academy, University of Gothenburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
1. All participants must give written informed consent
2. Woman or man aged 18 years or older
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 400
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100
Exclusion Criteria
1. Inability to give written informed consent
2. Inability to undergo blood sampling, e.g. due to lack of suitable blood vessels for sampling
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method